Topic: commercial manufacturing
Here is some news of note for the week.
India’s Dr. Reddy’s Laboratories says it will unload its API manufacturing business to the Middle East-based Neopharma.
Shire’s $1 billion plasma fractionation plant in Georgia has gone through three owners but is now officially open.
Israel-based Teva, whose pledge to unload manufacturing plants in its home country sparked strikes, is reportedly close to selling a site there.
GlaxoSmithKline will keep its cephalosporin antibiotics business but reorganize it to be more efficient, cutting nearly 200 jobs in the U.K.
Here is some other pharma manufacturing news of note for the week.
Bayer is laying off more than 225 workers at its complex in Berkeley, California, as it reorganizes manufacturing of its three hemophilia treatments.
Dr. Reddy’s, which is trying to slim down in the face of regulatory issues, is selling its U.S. antibiotics plant to UAE-based Neopharma.
Novartis’ traditional pill manufacturing will shoulder the brunt of a cost-cutting effort announced Tuesday as it looks to a future in biologic drugs.
After a three-year project, Pharmax Pharmaceuticals is now producing generic drugs in a small but new plant in Dubai.